NUR 641E ACTUAL MIDTERM EXAM STUDY GUIDE. (100% COMPLETE QUESTIONS AND CORRECT SOLUTIONS).

NUR 641E ACTUAL MIDTERM EXAM STUDY GUIDE. (100% COMPLETE QUESTIONS AND CORRECT SOLUTIONS). Prodrug -CORRECT- An inactive drug dosage form that is converted to an active metabolite by various biochemical reactions once it is inside the body. -Cytochrome P450 -Ex. Aspirin, psilocybin, heroin Bioavailability -CORRECT- the rate at and the extent to which a nutrient is absorbed and used -Affected by route of administration and drug dosage -Drug clearance (rate drug leaves circulation) -Steady state concentration -Affected by chemical stability, solubility, and first pass Steady state (of a drug) -CORRECT- stable level of drug in the body, occurs in 5 half-lives of the drug -rate of drug being added to system is equal to amount being eliminated from system Pharmacokinetics -CORRECT- The process by which drugs are absorbed, distributed within the body, metabolized, and excreted. -what the body does to the drug First pass -CORRECT- the fact that a medication in the GI tract passes through the liver before entering other organs does not -CORRECT- bioequivalence does/does not affect bioavailability Bioequivalence -CORRECT- relative therapeutic effectiveness of chemically equivalent drugs. Bioavailability (is affected by) -CORRECT- chemical instability -solubility -first pass metabolism Cytochrome P450 -CORRECT- enzymes that function to metabolize potentially toxic compounds, including drugs and products of endogenous metabolism such as bilirubin, principally in the liver. -genetics influence presence of enzymes -affects metabolism of warfarin, antidepressants, antiepileptics, and statins. -the levels of these drugs are higher when taken with certain drugs that are inhibitors (ex. warfarin with omeprazole) because there is competition for enzyme metabolism. -inducers lead to decreased plasma concentration of drug. cytochrome p450 inducer -CORRECT- An inducer increases the metabolism of a substrate resulting in a decreased level or effect of the substrate cytochrome p450 inhibitor -CORRECT- An inhibitor decreases the metabolism of a substrate resulting in an increased level or effect of the substrate. Clopidogrel -CORRECT- prodrug that must be activated by hepatic CYP2C19 metabolism; individuals who are poor metabolizers may not form the active metabolite and have reduced antiplatelet response half-life (determines) -CORRECT- how often a drug is administered 4-5 -CORRECT- steady state is reached in _-_ times the half-life Warfarin (MOA) -CORRECT- Vitamin K antagonist -Factors II, VII, IX, X -takes several days to take effect -monitor INR Vitamin K -CORRECT- warfarin antidote Heparin (MOA) -CORRECT- rapid anticoagulation by binding with antithrombin III and inhibits factors IXa, Xa, XIIa, and XIII -aPTT monitoring (low dose SQ does not require monitoring) Apixaban (MOA) -CORRECT- direct factor Xa inhibitor parenteral administration -CORRECT- directly into systemic circulation -poor absorption or unstable in GI tract (ex. heparin, insulin), rapid absorption, unable to take meds PO -IV, IM, SQ, ID IV -CORRECT- into the vein -can be given through bolus (rapid peak) or infusion (lower peak, longer duration) -ex. rocuronium (neuromuscular blocker) IM -CORRECT- aqua solutions absorbed rapidly -depot absorbed slowly in a nonaqueous solution such as polyethene glycol (simple diffusion) SQ -CORRECT- absorption via simple diffusion -constant, slow, and sustained effects -not for drugs that cause tissue irritation d/t pain and necrosis ID -CORRECT- diagnostic determination and allergy sensitivity inhalation -CORRECT- drug effects as rapid as IV bolus -minimizes systemic side effects of respiratory drugs oral -CORRECT- antidotes may be provided -most common, convenient, and economical method of drug administration -most complicated drug pathway -low gastric pH inactivates some drugs -20-60 minutes for effects -enteric, extended-release enteric-coated -CORRECT- protects the drug from stomach acid -delivers to less acidic intestine -useful for drugs that are acid labile or irritating to stomach (ex. omeprazole, aspirin) extended-release -CORRECT- control drug release -maintain therapeutic range over longer period -good for drugs with short half-life (i.e. morphine with half-life of 2-4 hours) aPTT -CORRECT- activated partial thromboplastin time 30-40 seconds -CORRECT- Normal activated partial thromboplastin time (APTT) 1.5-2.5 -CORRECT- therapeutic aPTT is x more than normal aPTT low dose heparin -CORRECT- 5000 units BID -does not require aPTT monitoring INR -CORRECT- international normalized ratio 2-3 (INR) -CORRECT- therapeutic INR for warfarin 1.1 -CORRECT- normal INR Dabigatran (Pradaxa) -CORRECT- direct thrombin inhibitor -anticoagulant -blood factor IIa inhibitor idarucizumab -CORRECT- antidote for dabigatran factor xa inhibitors -CORRECT- apixaban, edoxaban, rivarozaban, fondaparinux apixiban (MOA) -CORRECT- Factor Xa inhibitor -Eliquis Edoxaban (MOA) -CORRECT- Factor Xa inhibitor -Savaysa Rivaroxaban (MOA) -CORRECT- factor Xa inhibitor -Xarelto Fondaparinux (MOA) -CORRECT- factor Xa inhibitor -Arixtra Pulmonary Embolism -CORRECT- usually a clot from the leg that blocks the pulmonary vasculature -affects right ventricle d/t backing up of blood -can cause pulmonary hypertension -risk factors: immobility, obesity, hormonal birth control, smoking, HTN